Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.
Benjamin Solomon, MBBS, PhD, FRACP, consultant medical oncologist, professor, group leader, Molecular Therapeutics and Biomarkers Laboratory, Research Division, Peter MacCallum Cancer Center, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer (NSCLC).
In the randomized study, treatment-naïve patients with ALK-positive NSCLC were randomized 1:1 to receive 100 mg of lorlatinib (Lobrena) daily or 250 mg of crizotinib (Xalkori) twice daily. The results, which were presented during the 2020 ESMO Virtual Congress, showed that lorlatinib significantly prolonged progression-free survival (PFS) by blinded independent central review compared with crizotinib, meeting the primary end point of the study, says Solomon.
Further, the hazard ratio (HR) for PFS was 0.28, which was statistically significant, explains Solomon. The median PFS with lorlatinib has not yet been reached versus 9.3 months with crizotinib. Moreover, the 12-month landmark PFS rates were 78% and 39%, respectively.
The investigator-assessed PFS, which was a secondary end point of the study, had a positive HR of 0.21.
Finally, the overall response rate (ORR) was 76% with lorlatinib versus 58% with crizotinib, Solomon concludes.